Leerink Partners Starts Q32 Bio at Outperform With $40 Target
Leerink Partners began coverage of Q32 Bio with an Outperform rating and set a price target of $40.00 per share, according to Benzinga.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires reports that Leerink Partners initiated analyst coverage of Q32 Bio with an Outperform rating.
Benzinga said Leerink Partners set a price target of $40.00 per share for the company. The ratings information was published at 12:34 GMT on October 12, 2026.
why it matters
The analyst action may draw attention to Q32 Bio shares because it provides a new market assessment and a stated price target for the company.
instruments
sources
- Q32 Bio Initiated at Outperform by Leerink Partners — Dow Jones Newswires, 12 October 2026 at 12:34 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗